Nektar Therapeutics (NKTR) – Analysts’ Recent Ratings Changes
by Jessica Moore · The Cerbat GemNektar Therapeutics (NASDAQ: NKTR) has recently received a number of price target changes and ratings updates:
- 10/12/2026 – Nektar Therapeutics is now covered by UBS Group AG. They set a “neutral” rating and a $53.00 price target on the stock.
- 10/12/2026 – Nektar Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $130.00 price target on the stock.
- 10/9/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $178.00 price target on the stock.
- 10/9/2026 – Nektar Therapeutics is now covered by Raymond James Financial, Inc.. They set a “market perform” rating on the stock.
- 10/2/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $185.00 price target on the stock.
- 9/25/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $178.00 price target on the stock.
- 9/23/2026 – Nektar Therapeutics had its price target lowered by Wedbush from $80.00 to $50.00. They now have a “neutral” rating on the stock.
- 9/16/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $178.00 price target on the stock.
- 9/9/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $178.00 price target on the stock.
- 8/28/2026 – Nektar Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 8/24/2026 – Nektar Therapeutics was upgraded by TD Cowen to “strong-buy”.
- 8/21/2026 – Nektar Therapeutics is now covered by JPMorgan Chase & Co.. They set a “neutral” rating and a $65.00 price target on the stock.
Insiders Place Their Bets
In other Nektar Therapeutics news, CEO Howard Robin sold 418 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $71.98, for a total transaction of $30,087.64. Following the completion of the transaction, the chief executive officer directly owned 54,627 shares of the company’s stock, valued at $3,932,051.46. The trade was a 0.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is currently owned by corporate insiders.
Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines that use the body’s immune system to treat cancer and autoimmune diseases. The company’s research programs are based on proprietary drug-design and immunology technologies intended to improve the activity, targeting, or dosing of therapeutic agents.
Nektar’s pipeline has included NKTR-255, an investigational interleukin-15 receptor agonist designed to activate natural killer cells and support antitumor immune responses.